Alopecia
- National Alopecia Areata Foundation: Patient Resources
- Treatment Options for Alopecia Areata in Children and Adolescents
- Ritlecitinib Prescribing Information
- Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
- Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort
Atopic Dermatitis
- Which Clinical Measurement Tools for Atopic Dermatitis Severity Make the Most Sense in Clinical Practice?
- Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand
- New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis
- Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA–CHE): a new clinician reported outcome measure of CHE severity
- Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema
- Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis
- Therapeutic education in atopic dermatitis
- Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
- Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase 3 Trial
Prurigo Nodularis
- Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
- Prurigo Nodularis Signs and Symptoms – AAD Patient Resource
- Prurigo Nodularis Facts, Symptoms, Testing and Treatment – JAMA Patient Resource
- JAAD Health-related Quality of Life and Economic Burden of Prurigo Nodularis
- Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials (PRIME and PRIME2)
- Psychiatric Comorbidity and the Impact of Socioeconomic Status in Prurigo Nodularis
